WO2015028831A1 - Cxcl12 (chemokine (c-x-c motif) ligand 12) and igfbp2 inhibitors for the application in the treatment of diabetes mellitus associated pancreatic cancer - Google Patents
Cxcl12 (chemokine (c-x-c motif) ligand 12) and igfbp2 inhibitors for the application in the treatment of diabetes mellitus associated pancreatic cancer Download PDFInfo
- Publication number
- WO2015028831A1 WO2015028831A1 PCT/HU2014/000077 HU2014000077W WO2015028831A1 WO 2015028831 A1 WO2015028831 A1 WO 2015028831A1 HU 2014000077 W HU2014000077 W HU 2014000077W WO 2015028831 A1 WO2015028831 A1 WO 2015028831A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- inhibitors
- cxcl12
- cells
- pancreatic
- pancreatic cancer
- Prior art date
Links
- 206010061902 Pancreatic neoplasm Diseases 0.000 title claims abstract description 89
- 201000002528 pancreatic cancer Diseases 0.000 title claims abstract description 88
- 208000008443 pancreatic carcinoma Diseases 0.000 title claims abstract description 82
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 title claims abstract description 81
- 238000011282 treatment Methods 0.000 title claims abstract description 55
- 239000003112 inhibitor Substances 0.000 title claims abstract description 54
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 41
- 108010008951 Chemokine CXCL12 Proteins 0.000 title abstract description 55
- 102000006573 Chemokine CXCL12 Human genes 0.000 title abstract description 3
- 102000004372 Insulin-like growth factor binding protein 2 Human genes 0.000 title description 35
- 101100508040 Danio rerio igfbp2a gene Proteins 0.000 title 1
- 101150071737 igfbp2 gene Proteins 0.000 title 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims abstract description 66
- 230000005764 inhibitory process Effects 0.000 claims abstract description 16
- 229940079593 drug Drugs 0.000 claims abstract description 10
- 238000004519 manufacturing process Methods 0.000 claims abstract description 10
- 101001044940 Homo sapiens Insulin-like growth factor-binding protein 2 Proteins 0.000 claims abstract description 9
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 claims abstract description 9
- 102100022710 Insulin-like growth factor-binding protein 2 Human genes 0.000 claims abstract 7
- 102000005962 receptors Human genes 0.000 claims description 18
- 108020003175 receptors Proteins 0.000 claims description 18
- 239000000126 substance Substances 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 11
- 239000003981 vehicle Substances 0.000 claims description 8
- 230000019491 signal transduction Effects 0.000 claims description 7
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims description 2
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 2
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims description 2
- 206010056997 Impaired fasting glucose Diseases 0.000 claims description 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 3
- 208000001280 Prediabetic State Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000008103 glucose Substances 0.000 abstract description 49
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 45
- 201000001421 hyperglycemia Diseases 0.000 abstract description 40
- 230000001684 chronic effect Effects 0.000 abstract description 36
- 238000011161 development Methods 0.000 abstract description 11
- 230000003111 delayed effect Effects 0.000 abstract description 2
- 210000002705 pancreatic stellate cell Anatomy 0.000 description 103
- 210000004027 cell Anatomy 0.000 description 78
- 206010028980 Neoplasm Diseases 0.000 description 77
- 201000011510 cancer Diseases 0.000 description 47
- 230000014509 gene expression Effects 0.000 description 46
- 108090000623 proteins and genes Proteins 0.000 description 36
- 108090000964 Insulin-like growth factor binding protein 2 Proteins 0.000 description 34
- 230000035755 proliferation Effects 0.000 description 27
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 22
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 21
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 20
- 230000000694 effects Effects 0.000 description 18
- 238000001994 activation Methods 0.000 description 17
- 230000004913 activation Effects 0.000 description 16
- 108020004999 messenger RNA Proteins 0.000 description 16
- 238000000034 method Methods 0.000 description 16
- 210000000496 pancreas Anatomy 0.000 description 16
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 15
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 15
- 210000002744 extracellular matrix Anatomy 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 102000009618 Transforming Growth Factors Human genes 0.000 description 12
- 108010009583 Transforming Growth Factors Proteins 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 210000004881 tumor cell Anatomy 0.000 description 12
- 208000004104 gestational diabetes Diseases 0.000 description 11
- 230000037361 pathway Effects 0.000 description 11
- 230000028327 secretion Effects 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- 102000013275 Somatomedins Human genes 0.000 description 10
- 206010027476 Metastases Diseases 0.000 description 9
- 230000018109 developmental process Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- 230000002255 enzymatic effect Effects 0.000 description 8
- 210000002950 fibroblast Anatomy 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- YIQPUIGJQJDJOS-UHFFFAOYSA-N plerixafor Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CN1CCCNCCNCCCNCC1 YIQPUIGJQJDJOS-UHFFFAOYSA-N 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 102000019034 Chemokines Human genes 0.000 description 7
- 108010012236 Chemokines Proteins 0.000 description 7
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 7
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 7
- 239000006143 cell culture medium Substances 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000009401 metastasis Effects 0.000 description 7
- 210000004500 stellate cell Anatomy 0.000 description 7
- 210000000130 stem cell Anatomy 0.000 description 7
- 102000007469 Actins Human genes 0.000 description 6
- 108010085238 Actins Proteins 0.000 description 6
- 102000012422 Collagen Type I Human genes 0.000 description 6
- 108010022452 Collagen Type I Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- -1 TGF-Rs Proteins 0.000 description 6
- 230000004075 alteration Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000037319 collagen production Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 230000001394 metastastic effect Effects 0.000 description 6
- 206010061289 metastatic neoplasm Diseases 0.000 description 6
- 230000005012 migration Effects 0.000 description 6
- 238000013508 migration Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000010200 validation analysis Methods 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 102100022716 Atypical chemokine receptor 3 Human genes 0.000 description 5
- 208000000668 Chronic Pancreatitis Diseases 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 102000016621 Focal Adhesion Protein-Tyrosine Kinases Human genes 0.000 description 5
- 108010067715 Focal Adhesion Protein-Tyrosine Kinases Proteins 0.000 description 5
- 102000042092 Glucose transporter family Human genes 0.000 description 5
- 108091052347 Glucose transporter family Proteins 0.000 description 5
- 101000678890 Homo sapiens Atypical chemokine receptor 3 Proteins 0.000 description 5
- 102000043136 MAP kinase family Human genes 0.000 description 5
- 108091054455 MAP kinase family Proteins 0.000 description 5
- 206010033649 Pancreatitis chronic Diseases 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 238000003365 immunocytochemistry Methods 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 210000001819 pancreatic juice Anatomy 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 4
- 230000001364 causal effect Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000035605 chemotaxis Effects 0.000 description 4
- 230000004761 fibrosis Effects 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 239000000859 incretin Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 210000002460 smooth muscle Anatomy 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 108050006947 CXC Chemokine Proteins 0.000 description 3
- 102000019388 CXC chemokine Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 3
- 102100030708 GTPase KRas Human genes 0.000 description 3
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- JOOXLOJCABQBSG-UHFFFAOYSA-N N-tert-butyl-3-[[5-methyl-2-[4-[2-(1-pyrrolidinyl)ethoxy]anilino]-4-pyrimidinyl]amino]benzenesulfonamide Chemical compound N1=C(NC=2C=C(C=CC=2)S(=O)(=O)NC(C)(C)C)C(C)=CN=C1NC(C=C1)=CC=C1OCCN1CCCC1 JOOXLOJCABQBSG-UHFFFAOYSA-N 0.000 description 3
- 239000013614 RNA sample Substances 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- 108010023082 activin A Proteins 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 239000003405 delayed action preparation Substances 0.000 description 3
- 239000013583 drug formulation Substances 0.000 description 3
- 238000007459 endoscopic retrograde cholangiopancreatography Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 102000006495 integrins Human genes 0.000 description 3
- 108010044426 integrins Proteins 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000004068 intracellular signaling Effects 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 238000010197 meta-analysis Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 230000000284 resting effect Effects 0.000 description 3
- 150000004492 retinoid derivatives Chemical class 0.000 description 3
- 210000002536 stromal cell Anatomy 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 2
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 2
- 241000796533 Arna Species 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 2
- 102100031168 CCN family member 2 Human genes 0.000 description 2
- 108010061299 CXCR4 Receptors Proteins 0.000 description 2
- 102000012000 CXCR4 Receptors Human genes 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 102000009410 Chemokine receptor Human genes 0.000 description 2
- 108050000299 Chemokine receptor Proteins 0.000 description 2
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 101710165567 Extracellular signal-regulated kinase 1 Proteins 0.000 description 2
- 108091006027 G proteins Proteins 0.000 description 2
- 102000030782 GTP binding Human genes 0.000 description 2
- 108091000058 GTP-Binding Proteins 0.000 description 2
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 2
- 101000777550 Homo sapiens CCN family member 2 Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 241000764238 Isis Species 0.000 description 2
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 2
- 101710128836 Large T antigen Proteins 0.000 description 2
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 2
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 2
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 2
- 102100024192 Mitogen-activated protein kinase 3 Human genes 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108010002998 NADPH Oxidases Proteins 0.000 description 2
- 102000004722 NADPH Oxidases Human genes 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 108010058765 Oncogene Protein pp60(v-src) Proteins 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- HDAJDNHIBCDLQF-RUZDIDTESA-N SCH772984 Chemical compound O=C([C@@H]1CCN(C1)CC(=O)N1CCN(CC1)C=1C=CC(=CC=1)C=1N=CC=CN=1)NC(C=C12)=CC=C1NN=C2C1=CC=NC=C1 HDAJDNHIBCDLQF-RUZDIDTESA-N 0.000 description 2
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 2
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 2
- 108010017842 Telomerase Proteins 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000005809 anti-tumor immunity Effects 0.000 description 2
- 230000003305 autocrine Effects 0.000 description 2
- 210000000013 bile duct Anatomy 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000004709 cell invasion Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229960002448 dasatinib Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000007705 epithelial mesenchymal transition Effects 0.000 description 2
- 238000013266 extended drug release Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000003619 fibrillary effect Effects 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 102000043525 human CXCL12 Human genes 0.000 description 2
- 102000050770 human IGFBP2 Human genes 0.000 description 2
- 230000006028 immune-suppresssive effect Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 2
- 210000004923 pancreatic tissue Anatomy 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229960002169 plerixafor Drugs 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000003118 sandwich ELISA Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000005748 tumor development Effects 0.000 description 2
- 230000005751 tumor progression Effects 0.000 description 2
- 230000000381 tumorigenic effect Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Chemical compound OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 description 1
- MVWATCATLSSVBH-UHFFFAOYSA-N 1-[4-[2-[4-[(6-chloro-[1,3]dioxolo[4,5-b]pyridin-7-yl)amino]-5-propan-2-yloxyquinazolin-7-yl]oxyethyl]piperazin-1-yl]ethanone Chemical compound C=1C2=NC=NC(NC=3C(=CN=C4OCOC4=3)Cl)=C2C(OC(C)C)=CC=1OCCN1CCN(C(C)=O)CC1 MVWATCATLSSVBH-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 1
- 108020004463 18S ribosomal RNA Proteins 0.000 description 1
- BVAHPPKGOOJSPU-UHFFFAOYSA-N 2-[[5-chloro-2-[(5-methyl-2-propan-2-ylpyrazol-3-yl)amino]pyridin-4-yl]amino]-n-methoxybenzamide Chemical compound CONC(=O)C1=CC=CC=C1NC1=CC(NC=2N(N=C(C)C=2)C(C)C)=NC=C1Cl BVAHPPKGOOJSPU-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
- 238000004780 2D liquid chromatography Methods 0.000 description 1
- ZKRFOXLVOKTUTA-KQYNXXCUSA-N 9-(5-phosphoribofuranosyl)-6-mercaptopurine Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=S)=C2N=C1 ZKRFOXLVOKTUTA-KQYNXXCUSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000012109 Alexa Fluor 568 Substances 0.000 description 1
- 102100022524 Alpha-1-antichymotrypsin Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- CWHUFRVAEUJCEF-UHFFFAOYSA-N BKM120 Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(N2CCOCC2)=NC(N2CCOCC2)=N1 CWHUFRVAEUJCEF-UHFFFAOYSA-N 0.000 description 1
- 102100029648 Beta-arrestin-2 Human genes 0.000 description 1
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100021942 C-C motif chemokine 28 Human genes 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 101150067717 CXCL12 gene Proteins 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108010089448 Cholecystokinin B Receptor Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 101150093210 DPP4 gene Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102100037569 Dual specificity protein phosphatase 10 Human genes 0.000 description 1
- 102100037573 Dual specificity protein phosphatase 12 Human genes 0.000 description 1
- 102100023226 Early growth response protein 1 Human genes 0.000 description 1
- 102400000686 Endothelin-1 Human genes 0.000 description 1
- 101800004490 Endothelin-1 Proteins 0.000 description 1
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 1
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 1
- 101710165576 Extracellular signal-regulated kinase 2 Proteins 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102000016970 Follistatin Human genes 0.000 description 1
- 108010014612 Follistatin Proteins 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 description 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 1
- 101150099798 GSK1 gene Proteins 0.000 description 1
- 108010001498 Galectin 1 Proteins 0.000 description 1
- 102100021736 Galectin-1 Human genes 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000678026 Homo sapiens Alpha-1-antichymotrypsin Proteins 0.000 description 1
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 description 1
- 101000897477 Homo sapiens C-C motif chemokine 28 Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000924017 Homo sapiens Dual specificity protein phosphatase 1 Proteins 0.000 description 1
- 101000881127 Homo sapiens Dual specificity protein phosphatase 10 Proteins 0.000 description 1
- 101000881110 Homo sapiens Dual specificity protein phosphatase 12 Proteins 0.000 description 1
- 101001049697 Homo sapiens Early growth response protein 1 Proteins 0.000 description 1
- 101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 description 1
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 1
- 101001013150 Homo sapiens Interstitial collagenase Proteins 0.000 description 1
- 101001054649 Homo sapiens Latent-transforming growth factor beta-binding protein 2 Proteins 0.000 description 1
- 101001054646 Homo sapiens Latent-transforming growth factor beta-binding protein 3 Proteins 0.000 description 1
- 101000731000 Homo sapiens Membrane-associated progesterone receptor component 1 Proteins 0.000 description 1
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 1
- 101000861454 Homo sapiens Protein c-Fos Proteins 0.000 description 1
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 1
- 101000796022 Homo sapiens Thioredoxin-interacting protein Proteins 0.000 description 1
- 101000659879 Homo sapiens Thrombospondin-1 Proteins 0.000 description 1
- 101000860430 Homo sapiens Versican core protein Proteins 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 108091058560 IL8 Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102000008607 Integrin beta3 Human genes 0.000 description 1
- 108010020950 Integrin beta3 Proteins 0.000 description 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102100026236 Interleukin-8 Human genes 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102100027017 Latent-transforming growth factor beta-binding protein 2 Human genes 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 108010090306 Member 2 Subfamily G ATP Binding Cassette Transporter Proteins 0.000 description 1
- 102000013013 Member 2 Subfamily G ATP Binding Cassette Transporter Human genes 0.000 description 1
- 102100032399 Membrane-associated progesterone receptor component 1 Human genes 0.000 description 1
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 1
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 1
- 102100025725 Mothers against decapentaplegic homolog 4 Human genes 0.000 description 1
- 101710143112 Mothers against decapentaplegic homolog 4 Proteins 0.000 description 1
- 101100440286 Mus musculus Cntrl gene Proteins 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 102000008730 Nestin Human genes 0.000 description 1
- 108010088225 Nestin Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000016978 Orphan receptors Human genes 0.000 description 1
- 108070000031 Orphan receptors Proteins 0.000 description 1
- 108091008606 PDGF receptors Proteins 0.000 description 1
- 101150023417 PPARG gene Proteins 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 102100027584 Protein c-Fos Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 102100032350 Protransforming growth factor alpha Human genes 0.000 description 1
- 101150109738 Ptger4 gene Proteins 0.000 description 1
- 108050007494 Rho-related GTP-binding protein RhoE Proteins 0.000 description 1
- 102100039640 Rho-related GTP-binding protein RhoE Human genes 0.000 description 1
- 239000012891 Ringer solution Substances 0.000 description 1
- 108091006296 SLC2A1 Proteins 0.000 description 1
- 108091006299 SLC2A2 Proteins 0.000 description 1
- 108091006298 SLC2A3 Proteins 0.000 description 1
- 108091006300 SLC2A4 Proteins 0.000 description 1
- 102100038081 Signal transducer CD24 Human genes 0.000 description 1
- 108091027076 Spiegelmer Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 101150109894 TGFA gene Proteins 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 102100035115 Testin Human genes 0.000 description 1
- 241001441724 Tetraodontidae Species 0.000 description 1
- 102100031344 Thioredoxin-interacting protein Human genes 0.000 description 1
- 102100036034 Thrombospondin-1 Human genes 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 102100028437 Versican core protein Human genes 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 238000011226 adjuvant chemotherapy Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940040563 agaric acid Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 238000011316 allogeneic transplantation Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108010032967 beta-Arrestin 2 Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229950003628 buparlisib Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 231100000762 chronic effect Toxicity 0.000 description 1
- 229950009003 cilengitide Drugs 0.000 description 1
- AMLYAMJWYAIXIA-VWNVYAMZSA-N cilengitide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C(C)C)N(C)C(=O)[C@H]1CC1=CC=CC=C1 AMLYAMJWYAIXIA-VWNVYAMZSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- PZBCKZWLPGJMAO-UHFFFAOYSA-N copanlisib Chemical compound C1=CC=2C3=NCCN3C(NC(=O)C=3C=NC(N)=NC=3)=NC=2C(OC)=C1OCCCN1CCOCC1 PZBCKZWLPGJMAO-UHFFFAOYSA-N 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 108010072257 fibroblast activation protein alpha Proteins 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000009650 gentamicin protection assay Methods 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 238000005417 image-selected in vivo spectroscopy Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 102000028416 insulin-like growth factor binding Human genes 0.000 description 1
- 108091022911 insulin-like growth factor binding Proteins 0.000 description 1
- 238000012739 integrated shape imaging system Methods 0.000 description 1
- 229940125798 integrin inhibitor Drugs 0.000 description 1
- 229950001014 intetumumab Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 201000010985 invasive ductal carcinoma Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 238000003367 kinetic assay Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 238000010232 migration assay Methods 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 229940074923 mozobil Drugs 0.000 description 1
- KSERXGMCDHOLSS-LJQANCHMSA-N n-[(1s)-1-(3-chlorophenyl)-2-hydroxyethyl]-4-[5-chloro-2-(propan-2-ylamino)pyridin-4-yl]-1h-pyrrole-2-carboxamide Chemical compound C1=NC(NC(C)C)=CC(C=2C=C(NC=2)C(=O)N[C@H](CO)C=2C=C(Cl)C=CC=2)=C1Cl KSERXGMCDHOLSS-LJQANCHMSA-N 0.000 description 1
- RDSACQWTXKSHJT-NSHDSACASA-N n-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2s)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide Chemical compound C1CC1(C[C@H](O)CO)S(=O)(=O)NC=1C(OC)=CC(F)=C(F)C=1NC1=CC=C(I)C=C1F RDSACQWTXKSHJT-NSHDSACASA-N 0.000 description 1
- 210000005055 nestin Anatomy 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- LUYQYZLEHLTPBH-UHFFFAOYSA-N perfluorobutanesulfonyl fluoride Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)S(F)(=O)=O LUYQYZLEHLTPBH-UHFFFAOYSA-N 0.000 description 1
- 210000003668 pericyte Anatomy 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 238000011170 pharmaceutical development Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 108010005709 protein kinase C kinase Proteins 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 108091006082 receptor inhibitors Proteins 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 description 1
- 229960000215 ruxolitinib Drugs 0.000 description 1
- OUKYUETWWIPKQR-UHFFFAOYSA-N saracatinib Chemical compound C1CN(C)CCN1CCOC1=CC(OC2CCOCC2)=C(C(NC=2C(=CC=C3OCOC3=2)Cl)=NC=N2)C2=C1 OUKYUETWWIPKQR-UHFFFAOYSA-N 0.000 description 1
- 102000014452 scavenger receptors Human genes 0.000 description 1
- 108010078070 scavenger receptors Proteins 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229940068117 sprycel Drugs 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000000603 stem cell niche Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- 239000002700 tablet coating Substances 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960004066 trametinib Drugs 0.000 description 1
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4743—Insulin-like growth factor binding protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2014313964A AU2014313964A1 (en) | 2013-08-30 | 2014-08-27 | CXCL12 (Chemokine (C-X-C motif) Ligand 12) and IGFBP2 inhibitors for the application in the treatment of diabetes mellitus associated pancreatic cancer |
CA2922595A CA2922595A1 (en) | 2013-08-30 | 2014-08-27 | Cxcl12 (chemokine (c-x-c motif) ligand 12) and igfbp2 inhibitors for the application in the treatment of diabetes mellitus associated pancreatic cancer |
US14/915,590 US20160215053A1 (en) | 2013-08-30 | 2014-08-27 | Cxcl12 (chemokine (c-x-c motif) ligand 12) and igfbp2 inhibitors for the application in the treatment of diabetes mellitus associated pancreatic cancer |
EP14802110.8A EP3039035A1 (en) | 2013-08-30 | 2014-08-27 | Cxcl12 (chemokine (c-x-c motif) ligand 12) and igfbp2 inhibitors for the application in the treatment of diabetes mellitus associated pancreatic cancer |
JP2016537390A JP2016529278A (en) | 2013-08-30 | 2014-08-27 | CXCL12 (chemokine (C—X—C motif) ligand 12) and IGFBP2 inhibitor applied to the treatment of pancreatic cancer associated with diabetes mellitus |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU1300509A HUP1300509A2 (en) | 2013-08-30 | 2013-08-30 | Cxcl12 (chemokine (c-x-c motif) ligand 12) and igfbp2 (insulin-like growth factor binding protein 2) inhibitors for use in the treatment of diabetes-related pancreatic cancer |
HUP1300509 | 2013-08-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2015028831A1 true WO2015028831A1 (en) | 2015-03-05 |
WO2015028831A9 WO2015028831A9 (en) | 2015-04-23 |
Family
ID=89991239
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/HU2014/000077 WO2015028831A1 (en) | 2013-08-30 | 2014-08-27 | Cxcl12 (chemokine (c-x-c motif) ligand 12) and igfbp2 inhibitors for the application in the treatment of diabetes mellitus associated pancreatic cancer |
Country Status (7)
Country | Link |
---|---|
US (1) | US20160215053A1 (en) |
EP (1) | EP3039035A1 (en) |
JP (1) | JP2016529278A (en) |
AU (1) | AU2014313964A1 (en) |
CA (1) | CA2922595A1 (en) |
HU (1) | HUP1300509A2 (en) |
WO (1) | WO2015028831A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115128283A (en) * | 2022-07-20 | 2022-09-30 | 郑州大学第一附属医院 | Marker for severe acute pancreatitis and application thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009108797A1 (en) * | 2008-02-27 | 2009-09-03 | Mcw Research Foundation, Inc. | An engineered cxcl12 alpha locked dimer polypeptide |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5773419A (en) * | 1995-03-03 | 1998-06-30 | Falcon; Juan | Method of treating cancer with tannic acid |
CA2731416A1 (en) * | 1998-03-30 | 1999-10-07 | Northwest Biotherapeutics, Inc. | Therapeutic and diagnostic applications based on the role of the cxcr-4 gene in tumorigenesis |
EP2673363B1 (en) * | 2011-02-11 | 2017-08-23 | The Rockefeller University | Treatment of angiogenesis disorders |
-
2013
- 2013-08-30 HU HU1300509A patent/HUP1300509A2/en not_active IP Right Cessation
-
2014
- 2014-08-27 JP JP2016537390A patent/JP2016529278A/en active Pending
- 2014-08-27 WO PCT/HU2014/000077 patent/WO2015028831A1/en active Application Filing
- 2014-08-27 US US14/915,590 patent/US20160215053A1/en not_active Abandoned
- 2014-08-27 CA CA2922595A patent/CA2922595A1/en not_active Abandoned
- 2014-08-27 AU AU2014313964A patent/AU2014313964A1/en not_active Abandoned
- 2014-08-27 EP EP14802110.8A patent/EP3039035A1/en not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009108797A1 (en) * | 2008-02-27 | 2009-09-03 | Mcw Research Foundation, Inc. | An engineered cxcl12 alpha locked dimer polypeptide |
Non-Patent Citations (78)
Title |
---|
"Cancer Facts & Figures 2013", 2013, AMERICAN CANCER SOCIETY |
APTE MV; HABER PS; APPLEGATE TL; NORTON ID; MCCAUGHAN GW; KORSTEN MA ET AL.: "Periacinar stellate shaped cells in rat pancreas: identification, isolation, and culture", GUT, vol. 43, no. 1, 1998, pages 128 - 33, XP055353979, DOI: doi:10.1136/gut.43.1.128 |
APTE MV; HABER PS; DARBY SJ; RODGERS SC; MCCAUGHAN GW; KORSTEN MA ET AL.: "Pancreatic stellate cells are activated by proinflammatory cytokines: implications for pancreatic fibrogenesis", GUT, vol. 44, no. 4, 1999, pages 534 - 41 |
APTE MV; PHILLIPS PA; FAHMY RG; DARBY SJ; RODGERS S; MCCAUGHAN GW ET AL.: "Does alcohol directly stimulate pancreatic fibrogenesis? Studies with rat pancreatic stellate cells", GASTROENTEROLOGY, vol. 118, no. 4, 2000, pages 780 - 94, XP005138379, DOI: doi:10.1016/S0016-5085(00)70148-X |
APTE MV; PIROLA RC; WILSON JS: "Pancreatic stellate cells: a starring role in. normal and diseased pancreas", FRONT PHYSIOL., vol. 3, 2012, pages 344 |
ASAUMI H; WATANABE S; TAGUCHI M; TASHIRO M; OTSUKI M: "Externally applied pressure activates pancreatic stellate cells through the generation of intracellular reactive oxygen species", AM J PHYSIOL GASTROINTEST LIVER PHYSIOL, vol. 293, no. 5, 2007, pages G972 - 8 |
BACHEM MG; SCHNEIDER E; GROSS H; WEIDENBACH H; SCHMID RM; MENKE A ET AL.: "Identification, culture, and characterization of pancreatic stellate cells in rats and humans", GASTROENTEROLOGY, vol. 115, no. 2, 1998, pages 421 - 32, XP005688663, DOI: doi:10.1016/S0016-5085(98)70209-4 |
BACHEM MG; ZHOU S; BUCK K; SCHNEIDERHAN W; SIECH M: "Pancreatic stellate cells--role in pancreas cancer", LANGENBECKS ARCH SURG, vol. 393, no. 6, 2008, pages 891 - 900, XP019657908, DOI: doi:10.1007/s00423-008-0279-5 |
BACHET JB; MARECHAL R; DEMETTER P; BONNETAIN F; COUVELARD A; SVRCEK M ET AL.: "Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma", ANN ONCOL., vol. 23, no. 9, 2012, pages 2327 - 35 |
BAGGIO LL; DRUCKER DJ: "Biology of incretins: GLP-1 and GIP", GASTROENTEROLOGY, vol. 132, no. 6, 2007, pages 2131 - 57, XP022072503, DOI: doi:10.1053/j.gastro.2007.03.054 |
BALABANIAN K; LAGANE B; INFANTINO S; CHOW KY; HARRIAGUE J; MOEPPS B ET AL.: "The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 280, no. 42, 2005, pages 35760 - 6, XP003015681, DOI: doi:10.1074/jbc.M508234200 |
BALKWILL F: "Cancer and the chemokine network", NAT REV CANCER, vol. 4, no. 7, 2004, pages 540 - 50, XP009046388, DOI: doi:10.1038/nrc1388 |
BEN Q; CAI Q; LI Z; YUAN Y; NING X; DENG S ET AL.: "The relationship between new-onset diabetes mellitus and pancreatic cancer risk: a case-control study", EUR J CANCER., vol. 47, no. 2, 2011, pages 248 - 54, XP027576654 |
BEN Q; XU M; NING X; LIU J; HONG S; HUANG W ET AL.: "Diabetes mellitus and risk of pancreatic cancer: A meta-analysis of cohort studies", EUR J CANCER, vol. 47, no. 13, 2011, pages 1928 - 37, XP028266246, DOI: doi:10.1016/j.ejca.2011.03.003 |
BERNA MJ; SEIZ O; NAST JF; BENTEN D; BLAKER M; KOCH J ET AL.: "CCK1 and CCK2 receptors are expressed on pancreatic stellate cells and induce collagen production", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 285, no. 50, 2010, pages 38905 - 14 |
BRITTAN M; WRIGHT NA: "Gastrointestinal stem cells", J PATHOL., vol. 197, no. 4, 2002, pages 492 - 509 |
CHARI ST; LEIBSON CL; RABE KG; RANSOM J; DE ANDRADE M; PETERSEN GM: "Probability of pancreatic cancer following diabetes: a population-based study", GASTROENTEROLOGY, vol. 129, no. 2, 2005, pages 504 - 11, XP005314630, DOI: doi:10.1016/j.gastro.2005.05.007 |
CHARO C; HOLLA V; ARUMUGAM T; HWANG R; YANG P; DUBOIS RN ET AL.: "Prostaglandin E2 regulates pancreatic stellate cell activity-via the EP4 receptor", PANCREAS, vol. 42, no. 3, 2013, pages 467 - 74 |
CHEN R; BRENTNALL TA; PAN S; COOKE K; MOYES KW; LANE Z ET AL.: "Quantitative proteomics analysis -reveals that proteins differentially expressed in chronic pancreatitis are also frequently involved in pancreatic cancer", MOLECULAR & CELLULAR PROTEOMICS : MCP, vol. 6, no. 8, 2007, pages 1331 - 42, XP003031634, DOI: doi:10.1074/MCP.M700072-MCP200 |
CHEN R; PAN S; YI EC; DONOHOE S; BRONNER MP; POTTER JD ET AL.: "Quantitative proteomic profiling of pancreatic cancer juice", PROTEOMICS, vol. 6, no. 13, 2006, pages 3871 - 9, XP055160244, DOI: doi:10.1002/pmic.200500702 |
CHO RW; CLARKE MF: "Recent advances in cancer stem cells", CURR OPIN GENET DEV, vol. 18, no. 1, 2008, pages 48 - 53, XP022673194, DOI: doi:10.1016/j.gde.2008.01.017 |
CLEMMONS DR; SNYDER DK; BUSBY WH, JR: "Variables controlling the secretion of insulin-like growth factor binding protein-2 in normal human subjects", THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, vol. 73, no. 4, 1991, pages 727 - 33 |
DURR C; PFEIFER D; CLAUS R; SCHMITT-GRAEFF A; GERLACH UV; GRAESER R ET AL.: "CXCL12 mediates immunosuppression in the lymphoma microenvironment after allogeneic transplantation of hematopoietic cells", CANCER RESEARCH, vol. 70, no. 24, 2010, pages 10170 - 81 |
ERKAN M; ADLER G; APTE MV; BACHEM MG; BUCHHOLZ M; DETLEFSEN S ET AL.: "StellaTUM: current consensus and discussion on pancreatic stellate cell research", GUT, vol. 61, no. 2, 2012, pages 172 - 8 |
FITZNER B; WALZEL H; SPARMANN G; EMMRICH J; LIEBE S; JASTER R: "Galectin-1 is an inductor of pancreatic stellate cell activation", CELL SIGNAL., vol. 17, no. 10, 2005, pages 1240 - 7, XP025337427, DOI: doi:10.1016/j.cellsig.2004.12.012 |
FOULSTONE EMILY J ET AL: "Insulin-like growth factor binding protein 2 (IGFBP-2) promotes growth and survival of breast epithelial cells: novel regulation of the estrogen receptor.", ENDOCRINOLOGY MAY 2013, vol. 154, no. 5, May 2013 (2013-05-01), pages 1780 - 1793, XP002734164, ISSN: 1945-7170 * |
FUJITA H; OHUCHIDA K; MIZUMOTO K; EGAMI T; MIYOSHI K; MORIYAMA T ET AL.: "Tumor-stromal interactions with direct cell contacts enhance proliferation of human pancreatic carcinoma cells", CANCER SCI., vol. 100, no. 12, 2009, pages 2309 - 17 |
FUJITA H; OHUCHIDA K; MIZUMOTO K; NAKATAK; YU J; KAYASHIMA T: "alpha-Smooth Muscle Actin Expressing Stroma Promotes an Aggressive Tumor Biology in Pancreatic Ductal Adenocarcinoma", PANCREAS, 2010 |
GAO Z; WANG X; WU K; ZHAO Y; HU G: "Pancreatic stellate cells increase the invasion of human pancreatic cancer cells through the stromal cell-derived factor-1/CXCR4 axis", PANCREATOLOGY, vol. 10, no. 2-3, 2010, pages 186 - 93 |
HAMADA S; MASAMUNE A; TAKIKAWA T; SUZUKI N; KIKUTA K; HIROTA M ET AL.: "Pancreatic stellate cells enhance stem cell-like phenotypes in pancreatic cancer cells", BIOCHEM BIOPHYS RES COMMUN., vol. 421, no. 2, 2012, pages 349 - 54, XP028480377, DOI: doi:10.1016/j.bbrc.2012.04.014 |
HEINRICH EL; LEE W; U J; LOWY AM; KIM J: "Chemokine CXCL 12 activates dual CXCR4 and CXCR7-mediated signaling pathways in pancreatic cancer cells", J TRANSL MED., vol. 10, 2012, pages 68, XP021125295, DOI: doi:10.1186/1479-5876-10-68 |
HONG OK; LEE SH; RHEE M; KO SH; CHO JH; CHOI YH ET AL.: "Hyperglycemia and hyperinsulinemia have additive effects on activation and proliferation of pancreatic stellate cells: possible explanation of islet-specific fibrosis in type 2 diabetes mellitus", JOURNAL OF CELLULAR BIOCHEMISTRY, vol. 101, no. 3, 2007, pages 665 - 75 |
HU R; WANG YL; EDDERKAOUI M; LUGEA A; APTE MV; PANDOL SJ: "Ethanol augments PDGF-induced NADPH oxidase activity and proliferation in rat pancreatic stellate cells", PANCREATOLOGY, vol. 7, no. 4, 2007, pages 332 - 40 |
HUXLEY R; ANSARY-MOGHADDAM A; BERRINGTON DE GONZALEZ A; BARZI F; WOODWARD M: "Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies", BR J CANCER, vol. 92, no. 11, 2005, pages 2076 - 83 |
HWANG RF; MOORE T; ARUMUGAM T; RAMACHANDRAN V; AMOS KD; RIVERA A ET AL.: "Cancer-associated stromal fibroblasts promote pancreatic tumor progression", CANCER RESEARCH, vol. 68, no. 3, 2008, pages 918 - 26 |
JEE SH; OHRR H; SULL JW; YUN JE; JI M; SAMET JM: "Fasting serum glucose level and cancer risk in Korean men and women", JAMA, vol. 293, no. 2, 2005, pages 194 - 202 |
JESNOWSKI R; FURST D; RINGEL J; CHEN Y; SCHRODEL A; KLEEFF J ET AL.: "Immortalization of pancreatic stellate cells as an in vitro model of pancreatic fibrosis: deactivation is induced by matrigel and N-acetylcysteine", LAB INVEST., vol. 85, no. 10, 2005, pages 1276 - 91, XP055353980, DOI: doi:10.1038/labinvest.3700329 |
JIE W; WANG X; ZHANG Y; GUO J; KUANG D; ZHU P ET AL.: "SDF-1 alpha/CXCR4 axis is involved in glucose-potentiated proliferation and chemotaxis in rat vascular smooth muscle cells", INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, vol. 91, no. 5, 2010, pages 436 - 44 |
JUN XIA ET AL: "Targeting pancreatic cancer stem cells for cancer therapy", BBA - REVIEWS ON CANCER, ELSEVIER SCIENCE BV, AMSTERDAM, NL, vol. 1826, no. 2, 13 June 2012 (2012-06-13), pages 385 - 399, XP028516764, ISSN: 0304-419X, [retrieved on 20120620], DOI: 10.1016/J.BBCAN.2012.06.002 * |
KIKUTA K; MASAMUNE A; WATANABE T; ARIGA H; ITOH H; HAMADA S ET AL.: "Pancreatic stellate cells promote epithelial-mesenchymal transition in pancreatic cancer cells", BIOCHEM BIOPHYS RES COMMUN., vol. 403, no. 3-4, 2010, pages 380 - 4, XP027561197, DOI: doi:10.1016/j.bbrc.2010.11.040 |
KIMURA W; KURODA A; MAKUUCHI M: "Problems in the diagnosis and treatment of a so-called mucin-producing tumor of the pancreas", PANCREAS, vol. 16, no. 3, 1998, pages 363 - 9 |
KO SH; HONG OK; KIM JW; AHN YB; SONG KH; CHA BY ET AL.: "High glucose increases extracellular matrix production in pancreatic stellate cells by activating the renin-angiotensin system", JOURNAL OF CELLULAR BIOCHEMISTRY, vol. 98, no. 2, 2006, pages 343 - 55 |
KRAMAN M; BAMBROUGH PJ; ARNOLD JN; ROBERTS EW; MAGIERA L; JONES JO ET AL.: "Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha", SCIENCE, vol. 330, no. 6005, 2010, pages 827 - 30, XP055054344, DOI: doi:10.1126/science.1195300 |
KRYCZEK I; WEI S; KELLER E; LIU R; ZOU W: "Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis", AM J PHYSIOL CELL PHYSIOL., vol. 292, no. 3, 2007, pages C987 - 95, XP002471815, DOI: doi:10.1152/ajpcell.00406.2006 |
L6HR JM; JESNOWSKI.R: "Pancreatic stellate cells and pancreatic carcinoma: an unholy alliance", JOP, vol. 10, no. 4, 2009, pages 472 - 3 |
LI C; BALLUZ LS; FORD ES; OKORO CA; TSAI J; ZHAO G: "Association between diagnosed diabetes and self-reported cancer among U.S. adults: findings from the 2009 Behavioral Risk Factor Surveillance System", DIABETES CARE, vol. 34, no. 6, 2011, pages 1365 - 8 |
LI C; HEIDT DG; DALERBA P; BURANT CF; ZHANG L; ADSAY V ET AL.: "Identification of pancreatic cancer stem cells", CANCER RESEARCH, vol. 67, no. 3, 2007, pages 1030 - 7 |
M MIMEAULT ET AL: "Recent progress on normal and malignant pancreatic stem/progenitor cell research: therapeutic implications for the treatment of type 1 or 2 diabetes mellitus and aggressive pancreatic cancer", GUT, vol. 57, no. 10, 29 April 2008 (2008-04-29), pages 1456 - 1468, XP055160135, ISSN: 0017-5749, DOI: 10.1136/gut.2008.150052 * |
MAGEE JA; PISKOUNOVA E; MORRISON SJ: "Cancer stem cells: impact,. heterogeneity, and uncertainty", CANCER CELL, vol. 21, no. 3, 2012, pages 283 - 96, XP055023489, DOI: doi:10.1016/j.ccr.2012.03.003 |
MARCHESI F; MONTI P; LEONE BE; ZERBI A; VECCHI A; PIEMONTI L ET AL.: "Increased survival, proliferation, and migration in metastatic human pancreatic tumor cells expressing functional CXCR4", CANCER RESEARCH, vol. 64, no. 22, 2004, pages 8420 - 7 |
MASAMUNE A; SATOH A; WATANABE T; KIKUTA K; SATOH M; SUZUKI N ET AL.: "Effects of ethanol and its metabolites on human pancreatic stellate cells", DIG DIS SCI., vol. 55, no. 1, 2010, pages 04 - 1 |
MASAMUNE A; WATANABE T; KIKUTA K; SATOH K; SHIMOSEGAWA T: "NADPH oxidase plays a crucial role in the activation of pancreatic stellate cells", AM J PHYSIOL GASTROINTEST LIVER PHYSIOL, vol. 294, no. 1, 2008, pages G99 - G108 |
MEWS -P; PHILLIPS.P; FAHMY R; KORSTEN M; PIROLA R; WILSON J ET AL.: "Pancreatic stellate cells respond to inflammatory cytokines: potential role in chronic pancreatitis", GUT, vol. 50, no. 4, 2002, pages 535 - 41 |
MIAO Z; LUKER KE; SUMMERS BC; BERAHOVICH R; BHOJANI MS; REHEMTULLA A ET AL.: "CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature", PROC NATL ACAD SCI USA., vol. 104, no. 40, 2007, pages 15735 - 40, XP002481677, DOI: doi:10.1073/pnas.0610444104 |
MUNIRAJ T ET AL: "Diabetes and pancreatic cancer.", MINERVA GASTROENTEROLOGICA E DIETOLOGICA DEC 2012, vol. 58, no. 4, December 2012 (2012-12-01), pages 331 - 345, XP055160260, ISSN: 1121-421X * |
MURDOCH C: "CXCR4: chemokine receptor extraordinaire", IMMUNOL REV., vol. 177, 2000, pages 175 - 84 |
NAGASAWA T; TACHIBANA K; KISHIMOTO T: "A novel CXC chemokine PBSF/SDF-1 and its receptor CXCR4: their functions in development, hematopoiesis and HIV infection", SEMIN IMMUNOL., vol. 10, no. 3, 1998, pages 179 - 85 |
NAUCK M; SMITH U: "Incretin-based therapy: how do incretin mimetics and DPP-4 inhibitors fit into treatment algorithms for type 2 diabetic patients?", BEST PRACT RES CLIN ENDOCRINOL METAB., vol. 23, no. 4, 2009, pages 513 - 23, XP026581641, DOI: doi:10.1016/j.beem.2009.03.002 |
NAUMANN U; CAMERONI E; PRUENSTER M; MAHABALESHWAR H; RAZ E; ZERWES HG: "CXCR7 functions as a scavenger for CXCL12 and CXCL11", PLOS ONE, vol. 5, no. 2, 2010, pages E9175 |
NOMIYAMA Y; TASHIRO-M; YAMAGUCHI T; WATANABE S; TAGUCHI M; ASAUMI H ET AL.: "High glucose activates rat pancreatic stellate cells through protein kinase C and p38 mitogen-activated protein kinase pathway", PANCREAS, vol. 34, no. 3, 2007, pages 364 - 72 |
OHNISHI N; MIYATA T; OHNISHI H; YASUDA H; TAMADA K; UEDA N ET AL.: "Activin- A is an autocrine activator of rat pancreatic stellate cells: potential therapeutic role of follistatin for pancreatic fibrosis", GUT, vol. 52, no. 10, 2003, pages 1487 - 93 |
ORIMO A; GUPTA PB; SGROI DC; ARENZANA-SEISDEDOS F; DELAUNAY T; NAEEM R ET AL.: "Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion", CELL, vol. 121, no. 3, 2005, pages 335 - 48, XP009138583, DOI: doi:10.1016/j.cell.2005.02.034 |
PERRIN MC; TERRY MB; KLEINHAUS K; DEUTSCH L; YANETZ R; TIRAM E ET AL.: "Gestational diabetes as a risk factor for pancreatic cancer: a prospective cohort study", BMC MED., vol. 5, 2007, pages 25, XP021030244, DOI: doi:10.1186/1741-7015-5-25 |
PROOST P; STRUYF S; LOOS T; GOUWY M; SCHUTYSER E; CONINGS R ET AL.: "Coexpression and interaction of CXCL10 and CD26 in mesenchymal cells by synergising inflammatory cytokines: CXCL8 and CXCL10 are discriminative markers for autoimmune arthropathies", ARTHRITIS RES THER, vol. 8, no. 4, 2006, pages R107, XP021020591, DOI: doi:10.1186/ar1997 |
RU CHEN ET AL: "Quantitative proteomic profiling of pancreatic cancer juice", PROTEOMICS, vol. 6, no. 13, 1 July 2006 (2006-07-01), pages 3871 - 3879, XP055160244, ISSN: 1615-9853, DOI: 10.1002/pmic.200500702 * |
SCHNEIDER E; SCHMID-KOTSAS A; ZHAO J; WEIDENBACH H; SCHMID RM; MENKE A ET AL.: "Identification of mediators stimulating proliferation and matrix synthesis of rat pancreatic stellate cells", AM J PHYSIOL CELL PHYSIOL., vol. 281, no. 2, 2001, pages C532 - 43 |
SCHREIBER H; ROWLEY DA: "Cancer. Awakening immunity", SCIENCE, vol. 330, no. 6005, 2010, pages 761 - 2 |
See also references of EP3039035A1 |
SELLA T; CHODICK G; BARCHANA M; HEYMANN AD; PORATH A; KOKIA E ET AL.: "Gestational diabetes and risk of incident primary cancer: a large historical cohort study in Israel", CANCER CAUSES CONTROL., vol. 22, no. 11, 2011, pages 1513 - 20, XP019965096, DOI: doi:10.1007/s10552-011-9825-5 |
STEVENS RJ; RODDAM AW; BERAL V: "Pancreatic cancer in type 1 and young-onset diabetes: systematic review and meta-analysis", BR J CANCER, vol. 96, no. 3, 2007, pages 507 - 9 |
STRASSER-VOGEL B; BLUM WF; PAST R; KESSLER U; HOEFLICH A; MEILER B ET AL.: "Insulin-like growth factor (IGF)-I and -II and IGF-binding proteins-1, -2, and -3 in children and adolescents with diabetes mellitus: correlation with metabolic control and height attainment", THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, vol. 80, no. 4, 1995, pages 1207 - 13 |
TACHIBANA K; HIROTA S; IIZASA H; YOSHIDA H; KAWABATA K; KATAOKA Y ET AL.: "The chemokine receptor CXCR4 is essential for yascularization of the gastrointestinal tract", NATURE, vol. 393, no. 6685, 1998, pages 591 - 4, XP002922246, DOI: doi:10.1038/31261 |
TAHARA H; SATO K; YAMAZAKI Y; OHYAMA T; HORIGUCHI N; HASHIZUME H ET AL.: "Transforming growth factor-alpha activates pancreatic stellate cells and may be involved in matrix metalloproteinase- upregulation", LAB INVEST., vol. 93, no. 6, 2013, pages 720 - 32 |
TEICHER BA; FRICKER SP: "CXCL12 (SDF-1 )/CXCR4 pathway in cancer", CLIN CANCER RES., vol. 16, no. 11, 2010, pages 2927 - 31 |
VONLAUFEN A; JOSHI S; QU C; PHILLIPS PA; XU Z; PARKER NR ET AL.: "Pancreatic stellate cells: partners in crime with pancreatic cancer cells", CANCER RESEARCH, vol. 68, no. 7, 2008, pages 2085 - 93 |
W. ZHI ET AL: "Discovery and Validation of Serum Protein Changes in Type 1 Diabetes Patients Using High Throughput Two Dimensional Liquid Chromatography-Mass Spectrometry and Immunoassays", MOLECULAR & CELLULAR PROTEOMICS, vol. 10, no. 11, 1 November 2011 (2011-11-01), XP055061015, ISSN: 1535-9476, DOI: 10.1074/mcp.M111.012203 * |
XU Z; VONLAUFEN A; PHILLIPS PA; FIALA-BEER E; ZHANG X; YANG L ET AL.: "Role of pancreatic stellate cells in pancreatic cancer metastasis", AM J PATHOL., vol. 177, no. 5, 2010, pages 2585 - 96 |
ZHI W; SHARMA A; PUROHIT S; MILLER E; BODE B; ANDERSON SW ET AL.: "Discovery and validation of serum protein changes in type 1 diabetes patients using high throughput two dimensional liquid chromatography-mass spectrometry and immunoassays", MOLECULAR & CELLULAR PROTEOMICS : MCP, vol. 10, no. 11, 2011, pages M111 012203, XP055061015, DOI: doi:10.1074/mcp.M111.012203 |
Also Published As
Publication number | Publication date |
---|---|
JP2016529278A (en) | 2016-09-23 |
AU2014313964A1 (en) | 2016-03-17 |
US20160215053A1 (en) | 2016-07-28 |
EP3039035A1 (en) | 2016-07-06 |
HUP1300509A2 (en) | 2015-03-30 |
WO2015028831A9 (en) | 2015-04-23 |
CA2922595A1 (en) | 2015-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Thielen et al. | Identification of an anti-diabetic, orally available small molecule that regulates TXNIP expression and glucagon action | |
Barone et al. | Leptin, obesity and breast cancer: progress to understanding the molecular connections | |
Lee et al. | Obesity, adipokines and cancer: an update | |
Li et al. | Interleukin-17A promotes rheumatoid arthritis synoviocytes migration and invasion under hypoxia by increasing MMP2 and MMP9 expression through NF-κB/HIF-1α pathway | |
Guo et al. | Oncogenic role and therapeutic target of leptin signaling in breast cancer and cancer stem cells | |
Liao et al. | Dickkopf 4 positively regulated by the thyroid hormone receptor suppresses cell invasion in human hepatoma cells | |
EP3430163A1 (en) | Gene signatures for cancer detection and treatment | |
KR102344598B1 (en) | Composition for preventing or treating of liver cancer | |
Luo et al. | Insulin-like growth factor binding protein-1 (IGFBP-1) upregulated by Helicobacter pylori and is associated with gastric cancer cells migration | |
Wang et al. | Macrophage migration inhibitory factor promotes the invasion and metastasis of oral squamous cell carcinoma through matrix metalloprotein‐2/9 | |
Lu et al. | KMT5A downregulation participated in high glucose-mediated EndMT via upregulation of ENO1 expression in diabetic nephropathy | |
Lee et al. | Epstein-Barr viral product-containing exosomes promote fibrosis and nasopharyngeal carcinoma progression through activation of YAP1/FAPα signaling in fibroblasts | |
Lai et al. | Involvement of NADPH oxidase and NF-κB activation in CXCL1 induction by vascular endothelial growth factor in human endometrial epithelial cells of patients with adenomyosis | |
Chen et al. | Protective role of coxsackie-adenovirus receptor in the pathogenesis of inflammatory bowel diseases | |
Stangelberger et al. | Inhibition of human androgen-independent PC-3 and DU-145 prostate cancers by antagonists of bombesin and growth hormone releasing hormone is linked to PKC, MAPK and c-jun intracellular signalling | |
Xi et al. | A WISP1 antibody inhibits MRTF signaling to prevent the progression of established liver fibrosis | |
Chen et al. | CircRNA circ_0043533 facilitates cell growth in polycystic ovary syndrome by targeting miR-1179 | |
Qian et al. | The chemokine receptor‐CXCR 2 plays a critical role in the invasion and metastases of oral squamous cell carcinoma in vitro and in vivo | |
Dedinská et al. | Leptin–A new marker for development of post-transplant diabetes mellitus? | |
Xu et al. | MicroRNA-29b promotes cell sensitivity to Temozolomide by targeting STAT3 in glioma. | |
Hoffman et al. | Mesenteric adipose-derived stromal cells from Crohn’s disease patients induce protective effects in colonic epithelial cells and mice with colitis | |
US20160215053A1 (en) | Cxcl12 (chemokine (c-x-c motif) ligand 12) and igfbp2 inhibitors for the application in the treatment of diabetes mellitus associated pancreatic cancer | |
Tan et al. | Diabetes exacerbated sepsis-induced intestinal injury by promoting M1 macrophage polarization via miR-3061/Snail1 signaling | |
KR101906333B1 (en) | Use of leucine-zipper protein for diagnosing or treating Fatty liver disease | |
JP5564267B2 (en) | Use of inhibitors of p27 degradation, especially argylin and its derivatives, for the treatment of proliferative diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14802110 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2922595 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2016537390 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14915590 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2014313964 Country of ref document: AU Date of ref document: 20140827 Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2014802110 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014802110 Country of ref document: EP |